Overview

• Eli Lilly confirmed it hired Marks as senior vice president of molecule discovery and head of infectious disease, with his appointment effective this month.
• Marks told STAT his first day at Lilly Research Laboratories was Monday, while the company has not detailed his specific responsibilities.
• He led the FDA’s Center for Biologics Evaluation and Research for nearly a decade and played a key role in Operation Warp Speed and vaccine oversight.
• The move drew criticism over the regulator-to-industry pipeline, including a “scandal” claim from Trump adviser Calley Means, even as Leerink’s David Risinger said Lilly gains significant value from Marks’ experience.
• Marks’ March resignation followed disputes over vaccine policy, and his successor at CBER, Vinay Prasad, soon faced controversy over efforts to limit Sarepta’s Elevidys gene therapy.